Exhibit 99.1 Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results ˗ Company plans to engage with FDA based on interim data from the Phase 2 HELIOS clinical trial demonstrating improvements in pancreatic function, glycemic control, and vision in participants with Wolfram syndrome treated with AMX0035; topline data from all 12 participants at Week 24 anticipated in fall of 2024 ˗ Interim analysis from the ORION study of AMX0035 in progressive supranuclear palsy continues to be expected in mid-2 ...